{"preliminary_commentary":{"by_channel":{"x_thread":4,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"IFM 2022-01","nct_id":"NCT06353022","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ifm-2022-01-nct06353022. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IFm2022-01","arms":[{"description":"Patients treated with Teclistamab and Lenalidomide for finite duration.","label":"Teclistamab and Lenalidomide","type":"EXPERIMENTAL"},{"description":"Patients treated with Teclistamab and Talquetamab for finite duration","label":"Talquetamab andTeclistamab","type":"EXPERIMENTAL"}],"collaborators":["Janssen Pharmaceutica"],"completion_date":{"date":"2030-06-26","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":103,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Teclistamab","otherNames":["No more information"],"type":"DRUG"},{"name":"Talquetamab","otherNames":["No more information"],"type":"DRUG"},{"name":"Lenalidomide","otherNames":["No more information"],"type":"DRUG"},{"name":"Bortezomib","otherNames":["No more information"],"type":"DRUG"},{"name":"Daratumumab","otherNames":["No more information"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":["No more information"],"type":"DRUG"}],"last_update":"2026-03-17","lead_sponsor":"Nantes University Hospital","official_title":"Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-04-26","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Rate of sustained MRD negativity (NGS, 10^-5)","timeFrame":"38 months"},{"measure":"Rate of conversion from positive MRD to negative MRD (NGS, 10^-5)","timeFrame":"38 months"}],"references":[],"start_date":{"date":"2024-06-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT06353022"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ifm-2022-01-nct06353022"}